24 publications
| Name | Date | Type | Actions |
|---|---|---|---|
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
Public releases | ||
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
BALO : Notice of meeting Shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 28, 2024 at 11 a.m. at the Company's registered office, Magny-Vernois 70 200 LURE, in order to deliberate on the following agenda and draft resolutions |
Shareholders´s Meeting | ||
ANNUAL RESULTS 2023 (slideshow) 01.2023 Highlights |
Annual Report | ||
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
Public releases | ||
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
Public releases | ||
Vétoquinol announces opening of its first decentralized R&D center in Canada |
Public releases | ||
Vétoquinol to market and distribute Vetprofen in the United States |
Public releases | ||
3rd quarter revenues confirm promise of For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the |
Public releases | ||
Reports very good first half, confirming that 2007 performance is set to surpass targets |
Public releases |